Tin tức & Cập nhật

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
22 Nov 2021 bởiTristan Manalac

Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden
22 Nov 2021
Daratumumab-containing regimens safe, effective against multiple myeloma
Daratumumab-containing regimens safe, effective against multiple myeloma
21 Nov 2021

Adding daratumumab to backbone treatments against multiple myeloma (MM) yields high clinical efficacy and has an acceptable toxicity profile, a recent study has found. Such regimens are good treatment options for newly diagnosed (ND) and relapsed/refractory (RR) MM.

Daratumumab-containing regimens safe, effective against multiple myeloma
21 Nov 2021
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
19 Nov 2021
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
17 Nov 2021

The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.

Statins reduce hepatocellular carcinoma risk in cirrhotic patients
17 Nov 2021